Podcasts about RR

Joana Marques deseja ir de férias, mas não férias como as da influencer Mia Relógio.

A loucura volta a estúdio depois do Três por Todos. A Ana, Joana e Inês submetem-se à prova de português dos alunos do segundo ano e testam quantas palavras lêem por minuto. Mas de textos do século XIII.

En el capítulo 874 de este lunes, 9 de junio, @franaldaya te cuenta sobre la reunión de Milei con Meloni, la circular del Banco Central el viernes y una nueva rueda agitada en Wall Street. Además, Juan Pablo Álvarez con todo sobre los bonos en #LaFija, esta vez, en diálogo con Pedro Cavallo, head portfolio manager en Schroders.[Patrocinado] Conoce Deel, la plataforma de RR.HH. en la que confían miles de empresas en todo el mundo para gestionar y pagar a sus equipos globales. - ⁠⁠Conoce más

N Engl J Med 2001;345:1667-1675Background: Angiotensin II is a peptide hormone that is part of the renin–angiotensin–aldosterone system (RAAS). Angiotensin II is a potent vasoconstrictor and growth-stimulating hormone. Data suggested that it plays a role in ventricular remodeling and progression of heart failure. Although treatment with angiotensin-converting enzyme inhibitors (ACEi) reduce angiotensin II levels, physiologically active levels of angiotensin II may persist despite long-term therapy.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.The Valsartan Heart Failure Trial (Val-HeFT) sough to assess whether the angiotensin-receptor blocker valsartan, could reduce mortality and morbidity when added to optimal medical therapy in patients with systolic heart failure.Patients: Eligible patients had left ventricular ejection fraction less than 40% and left ventricular dilation, in addition to having clinical heart failure for at least 3 months with NYHA class II, III or IV symptoms. Patient also had to have been receiving a fixed-dose drug regimen for at least two weeks, that could include ACEi, diuretics, digoxin, and beta-blockers.There were many exclusion criteria. We mention some here: Postpartum cardiomyopathy, acute myocardial infarction within 3 months, coronary artery disease likely to require intervention, serum creatinine >2.5 mg/dL and life expectancy less than 5 years.Baseline characteristics: Patients were recruited from 302 centers in 16 countries. The trial randomized 5,010 patients – 2,511 randomized to receive valsartan and 2,499 to receive placebo.The average age of patients was 63 years and 80% were men. The average left ventricular ejection fraction was 27%. Cardiomyopathy was ischemic in 57% of the patients. The NYHA class was II in 62% of the patients, III in 36% of the patients and IV in 2%.Approximately 26% had diabetes and 12% had atrial fibrillation.At the time of enrollment, 86% were taking a diuretic, 67% were taking digoxin, 35% were taking beta-blockers, and 93% were taking ACEi.Procedures: The trial was double-blinded. The trial had an initial run-in period for 2 - 4 weeks where patients received placebo twice daily. This was performed to confirm patients' eligibility, clinical stability and compliance.Patients were assigned in a 1:1 ratio to receive valsartan or placebo. Randomization was stratified according to whether or not they were receiving a beta-blocker.Valsartan was started at a dose of 40 mg twice a day, and the dose was doubled every two weeks to the target dose of 160 mg twice a day. Placebo doses were adjusted in a similar way.Follow up occurred at 2, 4, and 6 months and every 3 months thereafter.Endpoints: The trial had two primary end points. The first was all-cause mortality. The second was the combined end point of mortality and morbidity, which was defined as cardiac arrest with resuscitation, hospitalization for heart failure, or administration of intravenous inotropic or vasodilator drugs for four hours or more without hospitalization.The estimated sample size was 5,000 patients. The sample size calculation assumed 20% relative risk reduction in mortality with valsartan assuming 906 patients would die during the trial. This sample size would provide the trial 90% power at 0.02 alpha. Alpha was 0.02 instead of the traditional 0.05 since the trial had two primary endpoints and to adjust for the interim analyses.Results: The target valsartan dose of 160 mg twice a day was achieved in 84% of the patients. The reduction in systolic blood pressure was greater with valsartan vs placebo – mean of 5.2 ± 15.8 mm with valsartan compared to 1.2 ± 14.8 mm Hg with placebo, at 4 months.All-cause mortality was not different between both groups (19.7% with valsartan vs 19.4% with placebo, RR: 1.02, 95% CI: 0.88 – 1.18; p= 0.80). The second co-primary endpoint was reduced with valsartan (28.8% vs 32.1%, RR: 0.87, 95% CI: 0.77 – 0.97; p= 0.009). This was driven by reduction in hospitalizations for heart failure (13.8% vs 18.2%). Cardiac arrest with resuscitation was 0.6% with valsartan and 1.0% with placebo. All-cause hospitalization was numerically lower with valsartan, however, this was not statistically significance (2,856 vs 3,106; p= 0.14). The mean change in ejection fraction was higher with valsartan (4.0% vs 3.2%; p= 0.001). More patients had improvement in NYHA classification with valsartan (23.1% vs 20.7%; p

While our host enjoys some well-earned R&R, we're cracking open the Six Figure Trucker vault to revisit one of our most insightful conversations — with none other than Peter Rizzo.Peter's not just a top-tier driveaway driver — he's a master of the craft. Known for his near-perfect on-time delivery rate, Peter's secret weapon is simple but powerful: planning. In this episode, he breaks down how thoughtful logistics can turn chaos into consistency — and why preparation equals profit.Whether you're new to driveaway or looking to level up, consider this your masterclass in “Driveaway 101.” Grab a notepad, and let Peter Rizzo show you how it's done — only on this episode of the #SixFigureTrucker. The Six-Figure Trucker is a weekly podcast about driveaway trucking brought to you by Norton Transport. For more information or to subscribe, please visit Six-FigureTrucker.com.

En nuestra portada de hoy, nombramos las claves internacionales más importantes del día. Entevista geopolítica con Luis Rodrigo de Castro, Profesor de RR.II. de la Universidad CEU San Pablo. Después, repasamos los protagonistas del día en Wall Street. Por último, miramos a los mercados en nuestro análisis con Pedro Escudero, fundador y CEO de Doma Perpetual.

Os últimos 23 anos de Pedro Caixinha são vertiginosos, desde o Sporting de Bölöni ao Santos de Neymar. É adjunto de Peseiro em quatro clubes e uma selecção antes de se assumir como treinador principal em 2010, na União de Leiria. Lá fora, é génio e figura no México, sobretudo no Santos Laguna. Apanhámo-lo de férias em Lisboa para apreciar a sua capacidade de comunicação e questioná-lo sobre a palavra resiliência.

Tara Graham is a Certified Integrative and Functional Nutritionist and Certified Terrain Advocate in Oncology Nutrition with a Degree in Complementary and Alternative Medicine. After her mother's terminal cancer diagnosis in 2014, Tara embarked on a mission to discover the root cause of disease.  She redefines the relationship with nourishment and food to uncover true healing within illness to include alternative cancer treatment and prevention, with a deep understanding of the intricacies of bio individuality and profound wellness. IG- @tarafuntionalhealth  Website: www.tarafunctionalhealth.com Email: tara@tarafunctionalhealth.com _______________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube

Joana Marques descobre quem é o médico de família de Gustavo Santos, e no fim acaba tudo (quase) nu, numa banheira de água gelada.

A Ana fala de flores raras e a conversa descamba para trocadilhos botânicos, Inês tem problemas com a saia das Marchas de Lisboa no IC19 e a Joana anda numa caça ao tesouro à procura de uma prescrição médica.

Bola Branca 12h45

Bola Branca 18h14

Falar de genocídio na Faixa de Gaza "é uma vergonha", diz embaixador de Israel7769f74d-f2

Title  – Ascites   Episode description RR discuss a case of ascites Student discount https://www.rlrcpsolvers.com/student-discounts/ IMG discount Use coupon code RLRIMG at check out  https://rlrcpsolvers.com/annual-plan

Joana Marques viu o documentário sobre Carolina Patrocínio e conta tudo.

Ana Galvão leva-nos até aos anos 80 e recorda a série "Verão Azul". Também os famosos anúncios a que já nos habitou estão de volta neste episódio.

Bola Branca 12h45

Bola Branca 18h15

Greta Thunberg e outros ativistas viajam até Gaza para "tentar abrir um corredor humanitário e romper o cerco"

Dois mortos e mais de 500 detidos em França durante celebraçõesf88de7ae-dc3e-f011-a5f1-0

Joana Marques fala-nos de Tiago Grila, da família que ele tem e da que gostaria de ter.

As Três da Manhã antecipam o dia da criança, com dois "jornalistas" de palmo e meio a trazerem as últimas notícias. No Extremamente Desagradável, Joana Marques fala-nos de Tiago Grila, da família que ele tem e da que gostaria de ter. No "Anda, Paula", perguntamos aos ouvintes que músicas não podem faltar nos bailes de verão.

Bola Branca 18h16

Bola Branca 12h45

A -35ºC e a mais de oito mil metros de altura: homem sobrevive a voo acidental de parapente na China

In this episode of the VJHemOnc podcast, join us for an insightful conversation with Dr Graham Collins, MA, MBBS, MRCP,... The post Recent advances in Hodgkin lymphoma treatment: novel regimens, ongoing trials & treating R/R disease appeared first on VJHemOnc.

Dois génios voltam a juntar-se: Tiago Grila voltou ao podcast do mestre e, por consequência, ao Extremamente Desagradável.

A Inês conhece uma pessoa que se chama Ana Galvão e tem a altura da Joana Marques, a Ana mostra o seu nabo gigante às amigas e descobrimos três médicos que enganaram o SNS, incluindo a Doutora Nhecos.

Dona Virgínia traz-nos como tema de semana o Três por Todos, mas os Tupperwares acabam por falar mais alto.

こんにちは。姿勢治療家（R）仲野孝明です。 この番組では、体の姿勢と生きる姿勢、より豊かに人生を生きるための姿勢力について話をさせていただいてます。 今回は、姿勢治療家(R)が考える健康の要素、6ヘルス（構造・睡眠・食・運動・精神・呼吸）の中の運動 ガーミンからカロスVERTEX2に2022年5月に変更し、まもなく3年になります。 ガジェットに多いバッテリー問題が出てきてもおかしくないですが、まだまだ十分現役です。 そんなカロスの最近の使い方は、『運動不足』にも気付ける警告灯のような頼もしい存在になっています。 カロス時計から気づける大事なこと ?日々の運動を見直す「きっかけ」に? カロスのトレーニングを見える化する3つの指標 トレーニング負荷（TL） リカバリー状態 トレーニング状態ステータス（不可率） 引き起こされた行動変化 カロスをただの時計せずに、運動習慣のパートナーに。 関連ブログ スマートウォッチ_カロスを3年使って、運動習慣が自然に手に入っていた事実 https://takaakinakano.com/coros_vertex2_2025/   体を見直す時間は、人生を見直す時間です。 ■Youtube｜姿勢治療家の「姿勢の医学」チャンネル 正しい姿勢と正しいカラダの使い方配信中 https://www.youtube.com/user/nakanoseitai ■twitter｜勢治療家仲野孝明公式 https://twitter.com/sisei_nakano ■有料動画講座｜いつでもどこでも学べる姿勢 一般社団法人 日本姿勢構造機構 https://shiseikk.jp/vimeo/ ■メルマガ登録｜仲野孝明メールマガジン ６ヘルスを軸にした日々の気づきコラム配信中。 http://takaakinakano.com/mail-register/ ■オンラインSHOP｜姿勢治療家印のグッズ販売 自分が使いたい商品をつくっちゃいました https://shop.senakano.jp/ ■公式ページ｜姿勢治療家仲野孝明 http://takaakinakano.com/ ■仲野整體東京青山｜姿勢治療家HEADOFFICE 治療のご相談はこちら https://senakano.jp/  

Bola Branca 18h15

Bola Branca 12h44

“Como é que alguém pode tolerar este horror?" Embaixador da Palestina na ONU chora ao falar de crianças em Gaza

Joana Marques fala do problema que Wuant teve com a Burger King e do problema que J Oliveira 10 teve com isso.

Lindsay was diagnosed at 31 years old with stage IV salivary gland cancer and later with mets to lungs, and brain. She went through 3 years of consistent surgeries and treatment. She knows conventional medicine kept her alive, but her will to thrive is the reason she is still here.  Overhauling the life she had, and choosing to follow her intuition set her on a completely different path. One where all of her desires became a reality. She has been a nurse for over 10 years and  is now a mom, to a beautiful 8 month old daughter and married to a man who sees and accepts all of her. She has been NED for 4 years and her intention is to spread the possibility of miracles. IG - https://www.instagram.com/lindsaykimmel/  email: linds.kimmel@gmail.com _________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com. To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube _____ If you've been listening to our podcast, you know just how important it is to address and release suppressed emotions. The evidence supporting this healing factor is growing, and we talked a lot about it in our podcast episode with Avinoam Lerner. Avinoam is a Cancer and Trauma specialist whose work highlights the cancer/trauma connection and addresses the root cause of suffering for enhanced immune function and more favorable treatment outcomes. He offers people facing cancer an evidence-based approach to increasing their odds of healing and recovery. Visit www.avinoamlerner.com for your personalized approach to releasing your suppressed emotions  VA link to www.avinoamlerner.com Mobilize Your Mind to Heal Your Body, Book your Free Discovery Session VA link to https://www.avinoamlerner.com/cancer-immune-enhancement Learn more about the Mindful Remission Program  VA link to https://www.avinoamlerner.com/cancer-wellness-programs 

Descobrimos com o Olivier que há cem anos houve uma Volta a Portugal em Cavalo e Daniel Oliveira é a Quarta da Manhã e responde a tudo sem chorar na entrevista

Bola Branca 12h46

Bola Branca 18h15

Joana Marques foi ouvir o novo podcast de Liliana Filipa, e convidou o Paulo Jorge, vindo directamente de 1980, a ouvir com ela.

Fr. Bobby Blood joins Patrick to discuss Fallen Away Family Members How is Faith a gift from God? What is the role of the community in staying in the faith? (19:11) Vicki - My siblings...most away from faith. I have a cousin who might want to come back. She goes to Mass, receives communion, and realizes she shouldn't do that. Siblings aren't talking to me. What can I do to help bring my siblings back? (19:11) Break 1 Mary - Fallen away member (daughter). Married a wonderful Christian. Said to my daughter he would do whatever she wanted. Moved around the country and has now gone to a Christian church. His mother was a fallen away Catholic. I can't say anything critical, but I want to bring them back. I think if she came back he would follow her. What are mistakes when trying to bring family back to the faith? (28:50) Patrick shares an email about the need for reflection in discerning what they did wrong in raising their kids Sue - I have a 30-year-old daughter and 27-year-old son. They don't believe in God. They were raised Catholic, Catholic school, etc. Wondering how to bring them back. We went through a divorce. I think they're dealing with a lot of hurt from it. (35:33) Patty - My question is...I have 2 nephews who are young adults. Sister has allowed them not to go to church, but they live in her house. Want to reach out and bring them back to church. My sister is blocking me from doing that, and I don't know what to do. (39:07) Break 2 (41:14) David - 2 children and my wife have left the church. All different situations. Daughter, 18, graduated last week and is a lesbian. Son, 23, he's into heavy metal. Wife, I think, is just laziness. There were a lot of changes in our parish and I think they didn't like it. I reminded them we're not here to worship you, we're here to worship God. Want to bring them back. (46:54) Carl - I encouraged my sisters to download the RR app to bring them back to the church. Shared something from Drew and she was impressed what she heard. What she did since then, I don't know, but she has the app and now has the opportunity to listen.

A Inês conta-nos o seu acidente de carro, a Ana explica porque choramos quando cortamos cebolas e, no Alerta Estupidez, a Joana é uma haltereofilista dopada que ESTÁ COM UMA PICA!

Joana Marques fala-nos do luxury lifestyle de Liliana Aguiar no Dubai.

Ana Galvão viaja até 1985 e recorda o programa "Totoloto" da RTP. Neste episódio, há ainda tempo para revisitarmos os clássicos anúncios ao qual já nos habituámos.

As Três recordam o bar que cheirava a incenso e outras peripécias do fim-de-semana em Madrid e partilham histórias da infância com os ouvintes – especialmente as que metem quedas e rabos esfolados.

Check out BeerBiceps SkillHouse's Designing For Clicks Course - https://bbsh.co.in/ra-yt-vid-dfcShare your guest suggestions hereLink - https://forms.gle/aoMHY9EE3Cg3Tqdx9BeerBiceps SkillHouse को Social Media पर Follow करे :-YouTube : https://www.youtube.com/channel/UC2-Y36TqZ5MH6N1cWpmsBRQ Instagram : https://www.instagram.com/beerbiceps_skillhouseWebsite : https://beerbicepsskillhouse.inFor any other queries EMAIL: support@beerbicepsskillhouse.comIn case of any payment-related issues, kindly write to support@tagmango.comLevel Supermind - Mind Performance App को Download करिए यहाँ से

Joana Marques traz de volta Domingos, ex-Casados à Primeira Vista e actual estrela da televisão portuguesa.

Joana Marques apresenta-nos Lourenço Amaral, o rosto de uma geração

Lancet 1999;353:2001-07Background: Beta-blockers directly reduce cardiac contractility and myocardial oxygen demand. For decades, they were avoided in patients with acute and chronic heart failure over concerns they would facilitate decompensation of the condition. The therapeutic cornerstones of treatment, prior to the modern era of clinical trials, focused on managing symptoms and quality of life with diuretics and inotropic agents like digoxin; however, new paradigms were arising that focused on addressing neurohormonal mechanisms of chronic disease that were over-activated in the failing heart. The first major success came with inhibition of the renin angiotensin aldosterone system with angiotensin converting enzyme inhibitors whose effect on mortality for patients with mild and severe forms of chronic heart failure were demonstrated in the V-HEFT II, CONSENSUS, and SOLVD trials. Additional benefits were demonstrated with the mineralocorticoid receptor antagonist spironolactone in the RALES trial. These drug classes primarily work by reducing afterload and volume retention. Appreciating why they work for improving cardiac performance and managing symptoms in heart failure patients is straightforward when we consider the major factors that effect cardiac stroke volume - preload, afterload and contractility; however, it is also noteworthy the effects these agents have on sudden death. How beta-blockade benefits the failing heart is less obvious (outside prevention of sudden death). Mechanistic studies in patients with chronic heart failure have consistently shown that when beta blockers are used for more than 1 month, left ventricular function improves. Beta blocker therapy appears to restore the density of beta-adrenergic receptors after they have been downregulated by the chronic overactivity of the sympathetic nervous system. The first major placebo-controlled RCT to demonstrate a mortality benefit used the non-selective beta blocker carvedilol. The trial was small and not originally designed to test mortality and was stopped early without clearly predefined stopping rules. Furthermore, 8% of total patients selected for participation in the trial were excluded prior to randomization after a 2 week, open-label run-in phase with the study drug, which saw 2% of all patients experience worsening heart failure or death representing 24 patients (the difference in total deaths between groups was 9 when the trial was stopped). The Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) was the first large scale trial designed to test the hypothesis that beta-blockade with metoprolol controlled/extended release (CR/XL) added to optimum medical therapy reduces mortality in patients with chronic systolic heart failure.Patients: Patients were recruited from 313 sites in 13 European countries and the United States. Eligible patients were men and women between the age of 40 to 80 years with symptomatic heart failure (NYHA class II-IV) for >/= 3 months before randomization. They had to be on a diuretic and ACE inhibitor for at least 2 weeks. Other drugs, including digoxin, could also be used. Patients also had to have an EF of /=68 beats per minute.Patients were excluded if: they had an MI or unstable angina within 28 days; had an indication or contraindication for treatment with beta-blocker; beta blockade within 6 weeks; heart failure due to systemic disease (i.e., amyloidosis) or alcohol abuse; scheduled or performed cardiac transplant; an ICD; procedures such as CABG or PCI planned or performed in the past 4 months; 2nd or 3rd degree AV block unless a pacemaker was present; unstable or decompensated heart failure defined by pulmonary edema or hypoperfusion or supine systolic BP 25% deviation of the number of observed versus expected consumed placebo tablets during the run-in period.Baseline characteristics: The mean age of patients was 64 years and approximately 78% were male. Slightly more than 30% of patients were above the age of 70. The average EF was 28%. The average SBP was 130 mmHg and heart rate was 82 bpm. Most patients had mild to moderate heart failure, with 41% in NYHA Class II, 56% in Class III, and only 3% in Class IV. Ischemic cardiomyopathy accounted for 65% of cases and nonischemic causes accounted for 35%. Most patients were on an ACE inhibitor or ARB (95%) and diuretic (90%). Digoxin was used in 63%. Trial procedures: Prior to randomization, the study was preceded by a single-blind, 2-week placebo run-in period. Patients meeting eligibility were then randomized to placebo or metoprolol CR/XL. The starting dose of placebo or metoprolol CR/XL was 12.5 mg daily for patients in NYHA class III or IV and 25 mg daily for patients in NYHA class II. The dose was doubled every 2 weeks until the target dose of 200 mg daily was reached. Patients were followed every 3 months.Endpoints: The primary outcome was all-cause mortality. It was estimated that 3,200 patients would need to be followed for 2.4 years to detect a 30% relative reduction in mortality based on annual mortality rate of 9.4% in the placebo group. This would achieve at least 80% power with a 2-sided alpha of 0.04. Patients were recruited faster then planned and so the final sample size of 3,991 patients increased the power of the study.The study was monitored by an independent safety committee and predefined stopping rules for efficacy were based on all-cause mortality, done when 25%, 50%, and 75% of expected deaths had occurred. Results: The trial was stopped early after the 2nd preplanned interim analysis when 50% of expected deaths had occurred. The mean duration of follow-up at the time of stopping was 1 year. The mean daily dose of metoprolol CR/XL was 159 mg once daily, with 87% receiving 100 mg or more and 64% receiving the target dose of 200 mg daily. In the placebo group, the corresponding values were 179 mg daily, 91% and 82%. The study drug was discontinued permanently in 14% of patients in the metoprolol group and 15% in the placebo group. Six months after randomization, heart rate decreased by 14 bpm in the metoprolol group compared to only 3 bpm in the placebo group. Systolic blood pressure decreased less in the metoprolol group (-2.1 vs 3.5 mmHg).Compared to placebo, metoprolol significantly reduced all-cause mortality (7.3% vs 10.8%; RR 0.66; 95% CI 0.53—0.81). Cardiovascular mortality accounted for 91% of all deaths; with sudden death accounting for 58% and death from worsening heart failure accounting for 24% of all deaths. All 3 of these causes of death were significantly reduced by metoprolol. The relative and absolute effects on death were greatest for patients with NYHA class III heart failure.Conclusions: In this trial of stable patients with mild to moderate chronic systolic heart failure, who were optimized on an ACEi or ARB and diuretic, metoprolol CR/XL significantly reduced all-cause mortality. Approximately 30 patients would need to be treated with metoprolol compared to placebo for 1 year to prevent 1 death. This trial represents a significant win for beta blockade in patients with chronic systolic heart failure. While the NNT in this trial is slightly higher than in SOLVD, it is important to appreciate that follow-up time in SOLVD was more than 3x longer. Limitations to external validity in this trial include the run-in period and stringent inclusion and exclusion criteria. Our enthusiasm is also tempered by early stopping, which has been found to be associated with false positive or exaggerated results but this concern is mitigated to some extent in this trial because the rules for early stopping were clearly defined in the protocol.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Joana Marques aproveita a boleia de Tânia Laranjo e vai até Marco de Canaveses verificar se a euromilionária ainda é rica ou não.